Akèy › Leksemi limfoblastik egi
Etid klinik pou Leksemi limfoblastik egi ap rekrite nan Etazini
134 etid pou Leksemi limfoblastik egi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX28 etid
- New York City, NY24 etid
- Seattle, WA21 etid
- Baldwin Park, CA21 etid
- Chicago, IL19 etid
- Atlanta, GA18 etid
- Memphis, TN16 etid
- Washington, DC16 etid
- Philadelphia, PA16 etid
- Boston, MA15 etid
- Los Angeles, CA14 etid
- Mountain View, CA13 etid
- Durham, NC13 etid
- Minneapolis, MN12 etid
- Cincinnati, OH12 etid
- Columbus, OH11 etid
- Salt Lake City, UT10 etid
- Tampa, FL10 etid
- Edison, NJ9 etid
- Portland, OR9 etid
- Baltimore, MD9 etid
- Aurora, CO8 etid
- Nashville, TN8 etid
- San Antonio, TX8 etid
- Miami, FL8 etid
- Charlotte, NC8 etid
- Birmingham, AL7 etid
- Cleveland, OH7 etid
- Denver, CO7 etid
- Pittsburgh, PA6 etid
- Detroit, MI6 etid
- Queens, NY6 etid
- Phoenix, AZ6 etid
- San Diego, CA6 etid
- Milwaukee, WI6 etid
- Oklahoma City, OK6 etid
- St. Louis, MO6 etid
- San Francisco, CA5 etid
- Indianapolis, IN5 etid
- Clifton, NJ5 etid
Pa eta
- Alabama7 etid
- Arizona6 etid
- Arkansas5 etid
- Ayiti3 etid
- Colorado12 etid
- Connecticut4 etid
- Distrik Columbia10 etid
- Florid19 etid
- Georgia19 etid
- Illinois20 etid
- Indiana6 etid
- Iowa5 etid
- Kalifòni40 etid
- Kansas5 etid
- Kentucky4 etid
- Lwizyàn6 etid
- Main3 etid
- Maryland16 etid
- Massachusetts15 etid
- Michigan8 etid
- Minnesota14 etid
- Mississippi3 etid
- Missouri6 etid
- Nebraska4 etid
- Nevada3 etid
- New Jersey11 etid
- New Mexico3 etid
- New York32 etid
- North Carolina21 etid
- Ohio21 etid
- Oklahoma8 etid
- Oregon10 etid
- Pennsylvania21 etid
- Rhode Island3 etid
- South Carolina5 etid
- South Dakota3 etid
- Tennessee22 etid
- Texas30 etid
- Utah10 etid
- Virginia9 etid
- Washington22 etid
- West Virginia4 etid
- Wisconsin9 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Ap rekrite
Laj 1 a 25 · Tout sèks · Mizajou Sep 30, 2026 · NCT05621291Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Sep 30, 2026 · NCT07572136CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Sep 30, 2026 · NCT06904066CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Ap rekriteFaz 2
Laj 3 a 65 · Tout sèks · Mizajou Sep 30, 2026 · NCT07328503A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Ap rekriteFaz 1
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Ap rekriteFaz 2
6 Months · Tout sèks · Mizajou Sep 28, 2026 · NCT06514794Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06144606Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children
Ap rekriteEtid obsèvasyon
4 Weeks – 18 Years · Tout sèks · Mizajou Sep 24, 2026 · NCT06529575Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06398457Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06308588Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06819475A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Ap rekriteFaz 1
Laj 0 a 18 · Tout sèks · Mizajou Sep 16, 2026 · NCT06173518A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06904482Cord Blood Transplant in Adults With Blood Cancers
Ap rekriteFaz 2
Laj 21 a 65 · Tout sèks · Mizajou Sep 11, 2026 · NCT05884333Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Ap rekriteFaz 1/2
Laj 16 a 75 · Tout sèks · Mizajou Sep 10, 2026 · NCT03104491Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT05334069Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Ap rekriteFaz 1
Laj 1 a 25 · Tout sèks · Mizajou Sep 1, 2026 · NCT06408194Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Ap rekriteFaz 1/2Volontè an sante akeyi
Jiska laj 50 · Tout sèks · Mizajou Sep 1, 2026 · NCT05322850First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07586618Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Aug 31, 2026 · NCT04881240CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Aug 28, 2026 · NCT07257419Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Ap rekriteFaz 1
1 Day – 21 Years · Tout sèks · Mizajou Aug 26, 2026 · NCT05857969Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06227026Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.